Once-weekly erythropoiesis-stimulating protein enters market.
Thompson
C A
CA
D000328:Adult; D000068256:Darbepoetin alfa; D017277:Drug Approval; D004920:Erythropoiesis / Q000187:drug effects*; D004921:Erythropoietin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use*; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D014481:United States; D014486:United States Food and Drug Administration
D006454:Hemoglobins; D004921:Erythropoietin; D000068256:Darbepoetin alfa